VistaGen Therapeutics Inc (VTGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.01M
Last updated: Nov 17, 2026 at 11:04 AM ET
VistaGen Therapeutics Inc (VTGN) Earnings: Report Dates and Results
VistaGen Therapeutics (VTGN) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, VistaGen Therapeutics reported EPS of -$0.24, above the -$0.37 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VTGN has an expected report date of Feb 10, 2027.
VTGN Earnings Call
The latest VTGN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, VTGN beat 21, missed 18 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $138000, down 46.5% from $258000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.24 | -$0.37 | -$0.38 - -$0.37 | +35.14% | Beat | N/A | 2 | 0 up, 2 down | Nov 13, 2026 | $138000 |
| Jun 30, 2026 | -$0.30 | -$0.29 | N/A | -3.45% | Miss | N/A | 2 | 0 up, 1 down | Aug 14, 2026 | $1.48M |
| Mar 31, 2026 | -$0.37 | -$0.42 | N/A | +11.90% | Beat | N/A | 3 | 2 up, 1 down | Jun 15, 2026 | $464000 |
| Dec 31, 2025 | -$0.45 | -$0.48 | -$0.54 - -$0.42 | +6.25% | Beat | N/A | 4 | 0 up, 3 down | Feb 12, 2026 | $303000 |
| Sep 30, 2025 | -$0.54 | -$0.44 | -$0.49 - -$0.35 | -22.73% | Miss | N/A | 3 | 0 up, 1 down | Nov 13, 2025 | $258000 |
| Jun 30, 2025 | -$0.47 | -$0.47 | -$0.47 - -$0.47 | 0.00% | In line | N/A | 1 | 0 up, 1 down | Aug 7, 2025 | $244000 |
| Mar 31, 2025 | -$0.44 | -$0.85 | N/A | +48.24% | Beat | N/A | 2 | 1 up, 0 down | Jun 17, 2025 | N/A |
| Dec 31, 2024 | -$0.46 | -$0.52 | -$0.54 - -$0.50 | +11.54% | Beat | N/A | 2 | 0 up, 1 down | Feb 13, 2025 | $234000 |
| Sep 30, 2024 | -$0.42 | -$0.39 | -$0.41 - -$0.37 | -7.69% | Miss | N/A | 4 | 0 up, 0 down | Nov 7, 2024 | $183000 |
| Jun 30, 2024 | -$0.35 | -$0.40 | -$0.41 - -$0.40 | +12.50% | Beat | N/A | 2 | 0 up, 0 down | Aug 13, 2024 | $84000 |
| Mar 31, 2024 | -$0.25 | -$0.36 | -$0.46 - -$0.27 | +30.56% | Beat | N/A | 4 | 0 up, 0 down | Jun 11, 2024 | $198000 |
| Dec 31, 2023 | -$0.22 | -$0.27 | -$0.39 - -$0.27 | +18.52% | Beat | N/A | 4 | 0 up, 0 down | Feb 13, 2024 | $411000 |
| Sep 30, 2023 | -$0.66 | -$0.68 | -$0.68 - -$0.68 | +2.94% | Beat | N/A | 1 | 0 up, 0 down | Nov 9, 2023 | $278000 |
| Jun 30, 2023 | -$0.94 | -$0.86 | N/A | -9.30% | Miss | N/A | N/A | 0 up, 0 down | Aug 10, 2023 | $177000 |
| Mar 31, 2023 | -$1.75 | -$1.50 | -$1.50 - -$1.50 | -16.67% | Miss | N/A | 1 | 0 up, 0 down | Jun 22, 2023 | $175600 |
| Dec 31, 2022 | -$1.50 | -$1.80 | -$2.40 - -$1.80 | +16.67% | Beat | N/A | 2 | 0 up, 0 down | Feb 7, 2023 | $179600 |
| Sep 30, 2022 | -$2.40 | -$0.60 | -$3.00 - -$0.60 | -300.00% | Miss | N/A | 3 | 0 up, 0 down | Nov 10, 2022 | N/A |
| Jun 30, 2022 | -$3.00 | -$2.25 | -$2.40 - -$2.10 | -33.33% | Miss | N/A | 2 | 0 up, 1 down | Aug 11, 2022 | $310100 |
| Mar 31, 2022 | -$0.09 | -$0.06 | -$0.06 - -$0.05 | -50.00% | Miss | N/A | 4 | 0 up, 0 down | Jun 23, 2022 | $1.33M |
| Dec 31, 2021 | -$1.50 | -$2.25 | -$2.40 - -$2.10 | +33.33% | Beat | N/A | 4 | N/A | Feb 10, 2022 | $179600 |
| Sep 30, 2021 | -$2.10 | -$2.25 | -$2.70 - -$1.20 | +6.67% | Beat | N/A | 4 | N/A | Nov 10, 2021 | $358000 |
| Jun 30, 2021 | -$1.20 | -$1.80 | N/A | +33.33% | Beat | N/A | 3 | N/A | Aug 12, 2021 | $354100 |
| Mar 31, 2021 | -$0.20 | -$0.05 | -$0.06 - -$0.04 | -300.00% | Miss | N/A | 4 | N/A | Jun 29, 2021 | $87800 |
| Dec 31, 2020 | -$2.10 | -$1.60 | -$1.80 - -$1.50 | -31.25% | Miss | N/A | 3 | N/A | Feb 11, 2021 | $313600 |
| Sep 30, 2020 | -$1.50 | -$0.70 | -$1.50 - $0.60 | -114.29% | Miss | N/A | 3 | N/A | Nov 12, 2020 | $334000 |
| Jun 30, 2020 | -$2.10 | -$3.00 | -$4.50 - -$3.00 | +30.00% | Beat | N/A | 2 | N/A | Aug 13, 2020 | $354100 |
| Mar 31, 2020 | -$0.07 | -$0.08 | -$0.10 - -$0.06 | +12.50% | Beat | N/A | 2 | N/A | Jun 29, 2020 | N/A |
| Dec 31, 2019 | -$4.50 | -$2.10 | -$2.10 - -$2.10 | -114.29% | Miss | N/A | 1 | N/A | Feb 13, 2020 | N/A |
| Sep 30, 2019 | -$3.90 | -$4.05 | -$4.50 - -$3.60 | +3.70% | Beat | N/A | 2 | N/A | Nov 7, 2019 | N/A |
| Jun 30, 2019 | -$4.50 | -$3.30 | -$3.30 - -$3.30 | -36.36% | Miss | N/A | 1 | N/A | Aug 16, 2019 | N/A |
| Mar 31, 2019 | -$0.17 | -$0.12 | -$0.12 - -$0.12 | -41.67% | Miss | N/A | 1 | N/A | Jun 25, 2019 | N/A |
| Dec 31, 2018 | -$7.20 | -$6.45 | -$9.01 - -$3.90 | -11.63% | Miss | N/A | 2 | N/A | Feb 12, 2019 | N/A |
| Sep 30, 2018 | -$9.00 | -$5.10 | -$5.71 - -$4.50 | -76.47% | Miss | N/A | 2 | N/A | Oct 29, 2018 | N/A |
| Jun 30, 2018 | -$6.00 | -$4.20 | -$4.20 - -$4.20 | -42.86% | Miss | N/A | 1 | N/A | Aug 14, 2018 | N/A |
| Mar 31, 2018 | -$0.09 | -$0.41 | N/A | +78.05% | Beat | N/A | 1 | N/A | Jun 26, 2018 | N/A |
| Dec 31, 2017 | -$7.50 | -$8.10 | N/A | +7.41% | Beat | N/A | 1 | N/A | Feb 12, 2018 | N/A |
| Sep 30, 2017 | -$0.53 | -$0.38 | N/A | -39.47% | Miss | N/A | N/A | N/A | Nov 9, 2017 | N/A |
| Jun 30, 2017 | -$8.40 | -$12.30 | N/A | +31.71% | Beat | N/A | N/A | N/A | Aug 14, 2017 | N/A |
| Mar 31, 2017 | -$0.31 | -$0.50 | N/A | +38.00% | Beat | N/A | N/A | N/A | Jun 29, 2017 | $1.25M |
| Dec 31, 2016 | -$10.20 | -$11.10 | N/A | +8.11% | Beat | N/A | N/A | N/A | Feb 13, 2017 | $1.25M |
Annual EPS
EPS for the fiscal year ended Mar 31, 2026 was -$1.83, after -$1.67 the year before. It was -$38.41 for the year ended Mar 31, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Mar 31, 2026 | -$1.83 | N/A |
| Mar 31, 2025 | -$1.67 | N/A |
| Mar 31, 2024 | -$2.07 | N/A |
| Mar 31, 2023 | -$8.65 | N/A |
| Mar 31, 2022 | -$4.89 | N/A |
| Mar 31, 2021 | -$5.90 | N/A |
| Mar 31, 2020 | -$12.97 | N/A |
| Mar 31, 2019 | -$22.37 | N/A |
| Mar 31, 2018 | -$16.52 | N/A |
| Mar 31, 2017 | -$38.41 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,900 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 2,915 | 9 | |
| 2026Q2 | Jun 30, 2026 | 2,946 | 8 | |
| 2026Q1 | Mar 31, 2026 | 3,574 | 9 | |
| 2025Q4 | Dec 31, 2025 | 3,474 | 7 | |
| 2025Q3 | Sep 30, 2025 | 3,884 | 9 | |
| 2025Q2 | Jun 30, 2025 | 3,786 | 9 | |
| 2025Q1 | Mar 31, 2025 | 3,100 | 9 | |
| 2024Q4 | Dec 31, 2024 | 4,014 | 7 |
2026Q3 Earnings Call
Opening remarks
Mark McPartland Senior Vice President, Investor Relations Thank you, Lisa, and good afternoon, everyone, and welcome to our conference call and webcast. Earlier this afternoon, we filed our quarterly report on Form 10-Q and issued a press release for our fiscal year 2026 third quarter, which ended December 31, 2025, and provided an update of our progress across our clinical stage neuroscience program. We encourage you to review the press release and 10-Q which are both available in the Investors section of our website. Before we begin, please note that we'll be making forward-looking statements regarding our business during today's call based on current expectations and information. These forward-looking statements speak only as of today. Except as law requires, we do not assume any duty to update any forward-looking statements made today or in the future. Of course, forward-looking statements involve risks and uncertainties, and our actual results could differ materially from those anticipated by any forward-looking statements we make today. Additional information concerning risks and factors that could affect our business and our financial results are included in our fiscal year 2026 third quarter Form 10-Q for the period ending December 31, 2025, and in future filings that we make with the SEC from time to time. Again, all of which are available in the Investors section of our website or on the SEC's website. With the formalities completed, we warmly welcome our stockholders, sell-side analysts and others interested in our programs in progress. I'm joined on our call today by Shawn Singh, our President and Chief Executive Officer; Joshua Prince, our Chief Operating Officer; and Nick Tressler, our Chief Financial Officer. Shawn will provide a brief business and clinical update, and Josh and Nick will be available to provide additional feedback during the Q&A portion of our call. After our remarks, we'll take questions from the sell-side analysts participating on the call. A replay of the webcast will be available in the Events section of the Investor page of our website. With that taken care of, I'd now like to turn the call over to our President and CEO, Shawn Singh.
Shawn Singh President and Chief Executive Officer Thank you, Mark, and good afternoon, everyone. It's been an important quarter for our team with the completion of the randomized portion of our PALISADE-3 Phase III trial in social anxiety disorder, as guided, and focused efforts to learn from the study's results and drive high-quality and efficient execution of our ongoing PALISADE-4 Phase III trial. We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization and operational enhancements to PALISADE-4.
Frequently Asked Questions About VTGN
When is VistaGen Therapeutics's next earnings date?
VistaGen Therapeutics's next earnings report is expected for Feb 10, 2027.
Did VTGN beat earnings estimates last quarter?
Yes. VistaGen Therapeutics reported EPS of -$0.24 for the quarter ended Sep 30, 2026, above the -$0.37 estimate, a 35.14% surprise.
What EPS do analysts expect from VTGN next quarter?
The consensus EPS estimate for VistaGen Therapeutics for the quarter ending Dec 31, 2026 is -$0.37 from 2 analysts, with estimates from -$0.37 to -$0.36.
How often does VTGN beat earnings estimates?
VistaGen Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +10.86%.
VTGN pages: Overview, Earnings, Forecast, Financials, Competitors